October 26, 2023
BioAge Labs, Inc., (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced plans to initiate a Phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) co-administered with the GLP-1/GIP receptor agonist tirzepatide for treatment of obesity. BioAge plans to initiate the...
December 05, 2022
BioAge Labs has concluded a Phase 1b study in which human volunteers undergoing 10 days of bed rest were shown to have their related muscle atrophy significantly attenuated by BGE-105. RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today...
May 16, 2022
BioAge Labs is developing a class of compounds that have been shown to inhibit the NLRP3 protein, which has been linked to all-cause mortality, in mouse models and human cells. These compounds can be taken orally and cross the blood-brain barrier. The full press release is included here. RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc. (“BioAge”,...
April 19, 2022
BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Below is the company's full press release. RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to...
March 21, 2022
A research paper that has just been peer reviewed and published in Nature has described how disrupting an immune pathway that is upregulated in aging decreases the lethality of COVID-19 in a mouse model. Mice with COVID-19 As the researchers explain, normal mice do not use the same angiotensin converting enzyme 2 (ACE2) as humans,...
April 28, 2021
BioAge Labs is off to a fast start in 2021, with two drugs in its pipeline now undergoing clinical trials and a third planned to start in the near future. BioAge Labs Building momentum After a $90 million Series C funding round closed late last year, BioAge has moved quickly to start the new year....